Functions of TNF and its Receptors in Renal Disease: Distinct Roles in Inflammatory Tissue Injury and Immune Regulation

Seminars in Nephrology

Volumn 27, Issue 3, 2007, Pages 286-308

  Vielhauer, Volker ^a   Mayadas, Tanya N ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ANCA associated vasculitis; diabetic nephropathy; endotoxemia; glomerulonephritis; hypertension; ischemia reperfusion injury; lupus nephritis; obstructive nephropathy; TNFR1; TNFR2

Indexed keywords

AUTOANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CROHN DISEASE; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULONEPHRITIS; HUMAN; IMMUNOREGULATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WEGENER GRANULOMATOSIS;

ANIMALS; HUMANS; INFLAMMATION; KIDNEY DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249076673     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.02.004     Document Type: Article

References (212)

1. Baud L., Oudinet J.P., Bens M., Noe L., Peraldi M.N., Rondeau E., et al. Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35 (1989) 1111-1118
2. Gomez-Guerrero C., Lopez-Armada M.J., Gonzalez E., and Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation. J Immunol 153 (1994) 5247-5255
3. Nakamura A., Johns E.J., Imaizumi A., Niimi R., Yanagawa Y., and Kohsaka T. Role of angiotensin II-induced cAMP in mesangial TNF-α production. Cytokine 19 (2002) 47-51
4. Noiri E., Kuwata S., Nosaka K., Tokunaga K., Juji T., Shibata Y., et al. Tumor necrosis factor-α mRNA expression in lipopolysaccharide-stimulated rat kidney. Chronological analysis of localization. Am J Pathol 144 (1994) 1159-1166
5. Neale T.J., Ruger B.M., Macaulay H., Dunbar P.R., Hasan Q., Bourke A., et al. Tumor necrosis factor-α is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 146 (1995) 1444-1454
6. Wüthrich R.P., Glimcher L.H., Yui M.A., Jevnikar A.M., Dumas S.E., and Kelley V.E. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 37 (1990) 783-792
7. Jevnikar A.M., Brennan D.C., Singer G.G., Heng J.E., Maslinski W., Wüthrich R.P., et al. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNFα. Kidney Int 40 (1991) 203-211
8. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
9. Aggarwal B.B., Samanta A., and Feldmann M. TNFα. In: Oppenheim J.J., and Feldmann M. (Eds). The cytokine reference Vol 1 (2001), Academic Press, San Diego 413-434
10. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72 (1975) 3666-3670
11. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89 (1992) 9784-9788
12. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2 (2002) 364-371
13. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712
14. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
15. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
16. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 346 (2002) 1349-1356
17. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
18. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
19. Kollias G., and Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 13 (2002) 315-321
20. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
21. De Rycke L., Kruithof E., Van Damme N., Hoffman I.E., Van den B.N., Van den B.F., et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48 (2003) 1015-1023
22. Eriksson C., Engstrand S., Sundqvist K.G., and Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF α. Ann Rheum Dis 64 (2005) 403-407
23. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
24. De Bandt M., Sibilia J., Le L.X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
25. Mor A., Bingham III C., Barisoni L., Lydon E., and Belmont H.M. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 32 (2005) 740-743
26. Stokes M.B., Foster K., Markowitz G.S., Ebrahimi F., Hines W., Kaufman D., et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 20 (2005) 1400-1406
27. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
28. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53 (1999) 457-465
29. Javaid B., and Quigg R.J. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics?. Kidney Int 67 (2005) 1692-1703
30. Feldmann M., and Pusey C.D. Is there a role for TNF-α in anti-neutrophil cytoplasmic antibody-associated vasculitis?. Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 17 (2006) 1243-1252
31. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 352 (2005) 351-361
32. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989) 244-247
33. Fong Y., Tracey K.J., Moldawer L.L., Hesse D.G., Manogue K.B., Kenney J.S., et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 170 (1989) 1627-1633
34. Pober J.S. Endothelial activation: intracellular signaling pathways. Arthritis Res. 4 Suppl 3 (2002) S109-S116
35. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 163 (1999) 1521-1528
36. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43 (2000) 38-47
37. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14 (2003) 185-191
38. Heller R.A., Song K., Fan N., and Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70 (1992) 47-56
39. Chan K.F., Siegel M.R., and Lenardo J.M. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13 (2000) 419-422
40. Karin M., and Lin A. NF-kB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
41. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
42. Cope A.P., Londei M., Chu N.R., Cohen S.B., Elliott M.J., Brennan F.M., et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94 (1994) 749-760
43. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185 (1997) 1573-1584
44. Isomaki P., Panesar M., Annenkov A., Clark J.M., Foxwell B.M., Chernajovsky Y., et al. Prolonged exposure of T cells to TNF down-regulates TCR ζ and expression of the TCR/CD3 complex at the cell surface. J Immunol 166 (2001) 5495-5507
45. Aspalter R.M., Wolf H.M., and Eibl M.M. Chronic TNF-α exposure impairs TCR-signaling via TNF-RII but not TNF-RI. Cell Immunol 237 (2005) 55-67
46. Zheng L., Fisher G., Miller R.E., Peschon J., Lynch D.H., and Lenardo M.J. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377 (1995) 348-351
47. Speiser D.E., Sebzda E., Ohteki T., Bachmann M.F., Pfeffer K., Mak T.W., et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol 26 (1996) 3055-3060
48. Herbein G., Mahlknecht U., Batliwalla F., Gregersen P., Pappas T., Butler J., et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395 (1998) 189-194
49. Kassiotis G., and Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193 (2001) 427-434
50. Kassiotis G., Kranidioti K., and Kollias G. Defective CD4 T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness. J Neuroimmunol 119 (2001) 239-247
51. McSorley S.J., Soldera S., Malherbe L., Carnaud C., Locksley R.M., Flavell R.A., et al. Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells. Immunity 7 (1997) 401-409
52. Fujimura T., Hirose S., Jiang Y., Kodera S., Ohmuro H., Zhang D., et al. Dissection of the effects of tumor necrosis factor-α and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunol 10 (1998) 1467-1472
53. Gordon C., and Wofsy D. Effects of recombinant murine tumor necrosis factor-α on immune function. J Immunol 144 (1990) 1753-1758
54. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., and Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179 (1994) 305-310
55. Kontoyiannis D., and Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 30 (2000) 2038-2047
56. Zhou T., Edwards III C.K., Yang P., Wang Z., Bluethmann H., and Mountz J.D. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 156 (1996) 2661-2665
57. Douni E., and Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin α, or the p55TNF-R. J Exp Med 188 (1998) 1343-1352
58. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 334 (1996) 1717-1725
59. MacEwan D.J. TNF ligands and receptors-a matter of life and death. Br J Pharmacol 135 (2002) 855-875
60. Grell M., Wajant H., Zimmermann G., and Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95 (1998) 570-575
61. Tartaglia L.A., Pennica D., and Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268 (1993) 18542-18548
62. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
63. Pinckard J.K., Sheehan K.C., and Schreiber R.D. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 272 (1997) 10784-10789
64. Bradley J.R., Thiru S., and Pober J.S. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol 146 (1995) 27-32
65. Madge L.A., Sierra-Honigmann M.R., and Pober J.S. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1). A nonpharmacological explanation for inhibition of TNF-mediated activation. J Biol Chem 274 (1999) 13643-13649
66. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., and Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci U S A 89 (1992) 4845-4849
67. Al Lamki R.S., Wang J., Skepper J.N., Thiru S., Pober J.S., and Bradley J.R. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 81 (2001) 1503-1515
68. Feldmann M., Brennan F.M., and Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 17 (1998) 217-228
69. Diez-Ruiz A., Tilz G.P., Zangerle R., Baier-Bitterlich G., Wachter H., and Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54 (1995) 1-8
70. Lantz M., Malik S., Slevin M.L., and Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2 (1990) 402-406
71. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200 (2004) 367-376
72. Galon J., Aksentijevich I., McDermott M.F., O'Shea J.J., and Kastner D.L. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol 12 (2000) 479-486
73. Ledgerwood E.C., Pober J.S., and Bradley J.R. Recent advances in the molecular basis of TNF signal transduction. Lab Invest 79 (1999) 1041-1050
74. Hsu H., Xiong J., and Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 81 (1995) 495-504
75. Hsu H., Huang J., Shu H.B., Baichwal V., and Goeddel D.V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996) 387-396
76. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., and Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8 (1998) 297-303
77. Park Y.C., Ye H., Hsia C., Segal D., Rich R.L., Liou H.C., et al. A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell 101 (2000) 777-787
78. Rothe M., Wong S.C., Henzel W.J., and Goeddel D.V. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78 (1994) 681-692
79. Pimentel-Muinos F.X., and Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 11 (1999) 783-793
80. Beyaert R., Vanhaesebroeck B., Declercq W., Van Lint J., Vandenabele P., Agostinis P., et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem 270 (1995) 23293-23299
81. Funk J.O., Walczak H., Voigtlander C., Berchtold S., Baumeister T., Rauch P., et al. Cutting edge: resistance to apoptosis and continuous proliferation of dendritic cells deficient for TNF receptor-1. J Immunol 165 (2000) 4792-4796
82. Floege J., Ostendorf T., and Wolf G. Growth factors and cytokines. In: Neilson E.G., and Couser W.G. (Eds). Immunologic renal diseases. 2nd ed. (2001), Lippincott Williams & Wilkins, Philadelphia 415-463
83. Aten J., Roos A., Claessen N., Schilder-Tol E.J., Ten Berge I.J., and Weening J.J. Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 11 (2000) 1426-1438
84. Niemir Z.I., Ondracek M., Dworacki G., Stein H., Waldherr R., Ritz E., et al. In situ upregulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kidney Dis 32 (1998) 80-92
85. Diamond J.R., and Pesek I. Glomerular tumor necrosis factor and interleukin 1 during acute aminonucleoside nephrosis. An immunohistochemical study. Lab Invest 64 (1991) 21-28
86. Onbe T., Kashihara N., Yamasaki Y., Makino H., and Ota Z. Expression of mRNA's of cytokines and growth factors in experimental glomerulonephritis. Res Commun Mol Pathol Pharmacol 86 (1994) 131-138
87. Ortiz A., Alonso J., Gomez-Chiarri M., Lerma J.L., Seron D., Condom E., et al. Fibronectin (FN) decreases glomerular lesions and synthesis of tumour necrosis factor-α (TNF-α), platelet-activating factor (PAF) and FN in proliferative glomerulonephritis. Clin Exp Immunol 101 (1995) 334-340
88. Tipping P.G., Leong T.W., and Holdsworth S.R. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 65 (1991) 272-279
89. Karkar A.M., Koshino Y., Cashman S.J., Dash A.C., Bonnefoy J., Meager A., et al. Passive immunization against tumour necrosis factor-α (TNF-α) and IL-1β protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin Exp Immunol 90 (1992) 312-318
90. Timoshanko J.R., Sedgwick J.D., Holdsworth S.R., and Tipping P.G. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 14 (2003) 1785-1793
91. Gomez-Chiarri M., Ortiz A., Lerma J.L., Lopez-Armada M.J., Mampaso F., Gonzalez E., et al. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab Invest 70 (1994) 449-459
92. Albaugh G., Kann B., Strande L., Vemulapalli P., Hewitt C., and Alexander J.B. Nicotine induces endothelial TNF-α expression, which mediates growth retardation in vitro. J Surg Res 99 (2001) 381-384
93. Eissner G., Lindner H., Konur A., Kreutz M., Andreesen R., and Holler E. Naive monocytes can trigger transendothelial migration of peripheral blood cells through the induction of endothelial tumour necrosis factor-α. Scand J Immunol 51 (2000) 251-261
94. Fouqueray B., Philippe C., Herbelin A., Perez J., Ardaillou R., and Baud L. Cytokine formation within rat glomeruli during experimental endotoxemia. J Am Soc Nephrol 3 (1993) 1783-1791
95. Kita T., Tanaka N., and Nagano T. The immunocytochemical localization of tumour necrosis factor and leukotriene in the rat kidney after treatment with lipopolysaccharide. Int J Exp Pathol 74 (1993) 471-479
96. Donnahoo K.K., Meng X., Ao L., Ayala A., Shames B.D., Cain M.P., et al. Differential cellular immunolocalization of renal tumour necrosis factor-α production during ischaemia versus endotoxaemia. Immunology 102 (2001) 53-58
97. Misseri R., Meldrum D.R., Dagher P., Hile K., Rink R.C., and Meldrum K.K. Unilateral ureteral obstruction induces renal tubular cell production of tumor necrosis factor-α independent of inflammatory cell infiltration. J Urol 172 (2004) 1595-1599
98. Kamanna V.S., Pai R., Bassa B., and Kirschenbaum M.A. Activation of mesangial cells with TNF-α stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase. Biochim Biophys Acta 1313 (1996) 161-172
99. Pai R., Ha H., Kirschenbaum M.A., and Kamanna V.S. Role of tumor necrosis factor-α on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J Am Soc Nephrol 7 (1996) 914-923
100. Radeke H.H., Meier B., Topley N., Floge J., Habermehl G.G., and Resch K. Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells. Kidney Int 37 (1990) 767-775
101. Wiggins R.C., Njoku N., and Sedor J.R. Tissue factor production by cultured rat mesangial cells. Stimulation by TNF α and lipopolysaccharide. Kidney Int 37 (1990) 1281-1285
102. Benador N.M., Grau G.E., Ruef C., and Girardin E.P. Endogenous TNF-α modulates the proliferation of rat mesangial cells and their prostaglandin E2 synthesis. Microvasc Res 50 (1995) 154-161
103. Pai R., Bassa B., Kirschenbaum M.A., and Kamanna V.S. TNF-α stimulates monocyte adhesion to glomerular mesangial cells. The role of intercellular adhesion molecule-1 gene expression and protein kinases. J Immunol 156 (1996) 2571-2579
104. Gerritsma J.S., Hiemstra P.S., Gerritsen A.F., Prodjosudjadi W., Verweij C.L., Van Es L.A., et al. Regulation and production of IL-8 by human proximal tubular epithelial cells in vitro. Clin Exp Immunol 103 (1996) 289-294
105. Peralta S.A., Mullin J.M., Knudsen K.A., and Marano C.W. Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Am J Physiol 270 (1996) F869-F879
106. Ortiz A., Lorz C., Catalan M.P., Danoff T.M., Yamasaki Y., Egido J., et al. Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 57 (2000) 969-981
107. Meldrum K.K., Meldrum D.R., Hile K.L., Yerkes E.B., Ayala A., Cain M.P., et al. p38 MAPK mediates renal tubular cell TNF-α production and TNF-α-dependent apoptosis during simulated ischemia. Am J Physiol 281 (2001) C563-C570
108. Takemura T., Yoshioka K., Murakami K., Akano N., Okada M., Aya N., et al. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 424 (1994) 459-464
109. Noronha I.L., Kruger C., Andrassy K., Ritz E., and Waldherr R. In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43 (1993) 682-692
110. Malide D., Russo P., and Bendayan M. Presence of tumor necrosis factor α and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26 (1995) 558-564
111. Honkanen E., Teppo A.M., Meri S., Lehto T., and Gronhagen-Riska C. Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis. Nephrol Dial Transplant 9 (1994) 1553-1559
112. Vielhauer V., Stavrakis G., and Mayadas T.N. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 115 (2005) 1199-1209
113. Cunningham P.N., Dyanov H.M., Park P., Wang J., Newell K.A., and Quigg R.J. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168 (2002) 5817-5823
114. Donnahoo K.K., Meng X., Ayala A., Cain M.P., Harken A.H., and Meldrum D.R. Early kidney TNF-α expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 277 (1999) R922-R929
115. Daemen M.A., van de Ven M.W., Heineman E., and Buurman W.A. Involvement of endogenous interleukin-10 and tumor necrosis factor-α in renal ischemia-reperfusion injury. Transplantation 67 (1999) 792-800
116. Kelly K.J., Williams Jr. W.W., Colvin R.B., and Bonventre J.V. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci U S A 91 (1994) 812-816
117. Donnahoo K.K., Shames B.D., Harken A.H., and Meldrum D.R. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol 162 (1999) 196-203
118. Ramesh G., and Reeves W.B. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110 (2002) 835-842
119. Kim Y.K., Choi T.R., Kwon C.H., Kim J.H., Woo J.S., and Jung J.S. Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Ren Fail 25 (2003) 909-922
120. Ramesh G., and Reeves W.B. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol 285 (2003) F610-F618
121. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
122. Tracey K.J., and Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45 (1994) 491-503
123. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318 (1988) 1481-1486
124. Iglesias J., Marik P.E., and Levine J.S. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-α as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 41 (2003) 62-75
125. Bertani T., Abbate M., Zoja C., Corna D., Perico N., Ghezzi P., et al. Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134 (1989) 419-430
126. Giroir B.P., Johnson J.H., Brown T., Allen G.L., and Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90 (1992) 693-698
127. Knotek M., Rogachev B., Wang W., Ecder T., Melnikov V., Gengaro P.E., et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59 (2001) 2243-2249
128. Wang W., Zolty E., Falk S., Basava V., Reznikov L., and Schrier R. Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol 291 (2006) F1090-F1095
129. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (1998) 943-952
130. Rodriguez-Iturbe B., Pons H., Herrera-Acosta J., and Johnson R.J. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59 (2001) 1626-1640
131. Kaneto H., Morrissey J.J., McCracken R., Ishidoya S., Reyes A.A., and Klahr S. The expression of mRNA for tumor necrosis factor α increases in the obstructed kidney of rats soon after unilateral ureteral ligation. Nephrology 2 (1996) 161-166
132. Guo G., Morrissey J., McCracken R., Tolley T., and Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 277 (1999) F766-F772
133. Misseri R., Meldrum D.R., Dinarello C.A., Dagher P., Hile K.L., Rink R.C., et al. TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am J Physiol 288 (2005) F406-F411
134. Guo G., Morrissey J., McCracken R., Tolley T., Liapis H., and Klahr S. Contributions of angiotensin II and tumor necrosis factor-α to the development of renal fibrosis. Am J Physiol 280 (2001) F777-F785
135. Muller D.N., Shagdarsuren E., Park J.K., Dechend R., Mervaala E., Hampich F., et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161 (2002) 1679-1693
136. Elmarakby A.A., Quigley J.E., Pollock D.M., and Imig J.D. Tumor necrosis factor α blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension 47 (2006) 557-562
137. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42 (1993) 450-456
138. DiPetrillo K., and Gesek F.A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24 (2004) 352-359
139. Kalantarinia K., Awad A.S., and Siragy H.M. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64 (2003) 1208-1213
140. Navarro J.F., Milena F.J., Mora C., Leon C., Claverie F., Flores C., et al. Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. 67 Suppl 99 (2005) S98-S102
141. Siragy H.M., Awad A., Abadir P., and Webb R. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-α in diabetic rats. Endocrinology 144 (2003) 2229-2233
142. Navarro J.F., Mora C., Muros M., and Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 16 (2005) 2119-2126
143. Navarro J.F., Mora C., Maca M., and Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42 (2003) 53-61
144. Moriwaki Y., Yamamoto T., Shibutani Y., Aoki E., Tsutsumi Z., Takahashi S., et al. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52 (2003) 605-608
145. Navarro J.F., Mora C., Muros M., and Garcia J. Urinary tumour necrosis factor-α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant 21 (2006) 3428-3434
146. Vendrell J., Broch M., Fernandez-Real J.M., Gutierrez C., Simon I., Megia A., et al. Tumour necrosis factor receptors (TNFRs) in type 2 diabetes. Analysis of soluble plasma fractions and genetic variations of TNFR2 gene in a case-control study. Diabet Med 22 (2005) 387-392
147. Wang Y., Ng M.C., So W.Y., Ma R., Ko G.T., Tong P.C., et al. Association between tumour necrosis factor-α G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol Dial Transplant 20 (2005) 2733-2738
148. Ozen S., Saatci U., Tinaztepe K., Bakkaloglu A., and Barut A. Urinary tumor necrosis factor levels in primary glomerulopathies. Nephron 66 (1994) 291-294
149. Tomosugi N.I., Cashman S.J., Hay H., Pusey C.D., Evans D.J., Shaw A., et al. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J Immunol 142 (1989) 3083-3090
150. Le Hir M., Haas C., Marino M., and Ryffel B. Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. Lab Invest 78 (1998) 1625-1631
151. Chen Y.M., Ng Y.Y., Lin S.L., Chiang W.C., Lan H.Y., and Tsai T.J. Pentoxifylline suppresses renal tumour necrosis factor-α and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 19 (2004) 1106-1115
152. Lan H.Y., Yang N., Metz C., Mu W., Song Q., Nikolic-Paterson D.J., et al. TNF-α up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med 3 (1997) 136-144
153. Karkar A.M., Smith J., and Pusey C.D. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-α. Nephrol Dial Transplant 16 (2001) 518-524
154. Khan S.B., Cook H.T., Bhangal G., Smith J., Tam F.W., and Pusey C.D. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67 (2005) 1812-1820
155. Jacobs M., Brown N., Allie N., Chetty K., and Ryffel B. Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity. Pathobiology 68 (2000) 68-75
156. Rosenkranz A.R., Knight S., Sethi S., Alexander S.I., Cotran R.S., and Mayadas T.N. Regulatory interactions of αβ and γδ T cells in glomerulonephritis. Kidney Int 58 (2000) 1055-1066
157. Rosenkranz A.R., Mendrick D.L., Cotran R.S., and Mayadas T.N. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 103 (1999) 649-659
158. Hindmarsh E.J., and Marks R.M. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J Immunol 160 (1998) 6128-6136
159. Boswell J.M., Yui M.A., Burt D.W., and Kelley V.E. Increased tumor necrosis factor and IL-1 β gene expression in the kidneys of mice with lupus nephritis. J Immunol 141 (1988) 3050-3054
160. Brennan D.C., Yui M.A., Wüthrich R.P., and Kelley V.E. Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J Immunol 143 (1989) 3470-3475
161. Yokoyama H., Kreft B., and Kelley V.R. Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 47 (1995) 122-130
162. Tsai C.Y., Wu T.H., Huang S.F., Sun K.H., Hsieh S.C., Han S.H., et al. Abnormal splenic and thymic IL-4 and TNF-α expression in MRL-lpr/lpr mice. Scand J Immunol 41 (1995) 157-163
163. Debets J.M., Van der Linden C.J., Dieteren I.E., Leeuwenberg J.F., and Buurman W.A. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 141 (1988) 1197-1201
164. Neuwirth R., Singhal P., Diamond B., Hays R.M., Lobmeyer L., Clay K., et al. Evidence for immunoglobulin Fc receptor-mediated prostaglandin 2 and platelet-activating factor formation by cultured rat mesangial cells. J Clin Invest 82 (1988) 936-944
165. Santiago A., Satriano J., DeCandido S., Holthöfer H., Schreiber R., Unkeless J., et al. A specific Fcγ receptor on cultured rat mesangial cells. J Immunol 143 (1989) 2575-2582
166. Moore K.J., Yeh K., Naito T., and Kelley V.R. TNF-α enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol 157 (1996) 427-432
167. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., and Avalos-Diaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 7 (1998) 154-158
168. Aringer M., and Smolen J.S. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 5 (2003) 172-177
169. Maury C.P., and Teppo A.M. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 32 (1989) 146-150
170. Studnicka-Benke A., Steiner G., Petera P., and Smolen J.S. Tumour necrosis factor α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35 (1996) 1067-1074
171. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J.M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24 (1997) 303-308
172. Lee Y.H., Harley J.B., and Nath S.K. Meta-analysis of TNF-α promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 14 (2006) 364-371
173. Deguchi Y., and Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol 85 (1991) 392-395
174. Edwards III C.K., Zhou T., Zhang J., Baker T.J., De M., Long R.E., et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α. J Immunol 157 (1996) 1758-1772
175. Segal R., Dayan M., Zinger H., and Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline. Lupus 10 (2001) 23-31
176. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
177. Horiuchi T., Kiyohara C., Tsukamoto H., Sawabe T., Furugo I., Yoshizawa S., et al. A functional M196R polymorphism of tumor necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis. Ann Rheum Dis 66 (2007) 320-324
178. Huugen D., Xiao H., van Esch A., Falk R.J., Peutz-Kootstra C.J., Buurman W.A., et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-α. Am J Pathol 167 (2005) 47-58
179. Pfister H., Ollert M., Frohlich L.F., Quintanilla-Martinez L., Colby T.V., Specks U., et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 104 (2004) 1411-1418
180. Little M.A., Smyth C.L., Yadav R., Ambrose L., Cook H.T., Nourshargh S., et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106 (2005) 2050-2058
181. Little M.A., Bhangal G., Smyth C.L., Nakada M.T., Cook H.T., Nourshargh S., et al. Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17 (2006) 160-169
182. Bartolucci P., Ramanoelina J., Cohen P., Mahr A., Godmer P., Le Hello C., et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41 (2002) 1126-1132
183. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 41 (2002) 1303-1307
184. Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levy J., et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15 (2004) 717-721
185. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
186. Stone J.H., Holbrook J.T., Marriott M.A., Tibbs A.K., Sejismundo L.P., Min Y.I., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54 (2006) 1608-1618
187. Herrero-Fresneda I., Franquesa M., Torras J., Vidal A., Aran J., Pluvinet R., et al. Role of cold ischemia in acute rejection: characterization of a humoral-like acute rejection in experimental renal transplantation. Transplant Proc 37 (2005) 3712-3715
188. Gasser M., Waaga-Gasser A.M., Kist-van Holthe J.E., Yuan X., Lenhard S.M., Abdallah K.A., et al. Chronic rejection: insights from a novel immunosuppressive-free model of kidney transplantation. J Am Soc Nephrol. 15 (2004) 687-694
189. Krogerus L., Soots A., Bruggeman C., Loginov R., Ahonen J., and Lautenschlager I. CMV increases TNF-α expression in a rat kidney model of chronic rejection. Transplant Proc 35 (2003) 803
190. Oliveira S.G., Oliveira I.B., Abensur H., Araujo M.R., Romao J.E., and Noronha I.L. Differential expression of cytokines, growth factors, and α-smooth muscle actin in renal allograft biopsies. Transplant Proc 34 (2002) 479-481
191. Hribova P., Kotsch K., Brabcova I., Vitko S., Volk H.D., and Lacha J. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc 37 (2005) 760-763
192. Strehlau J., Pavlakis M., Lipman M., Shapiro M., Vasconcellos L., Harmon W., et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 94 (1997) 695-700
193. Zegarska J., Paczek L., Pawlowska M., Podrzucki W., Rowinski W., Malanowski P., et al. Quantitative gene expression of TGF-β1, TNF-α, IL-1β, and IL-6 in the renal artery wall of chronically rejected human renal allografts. Transplant Proc 34 (2002) 3176-3179
194. Melk A., Henne T., Kollmar T., Strehlau J., Latta K., Offner G., et al. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children. Kidney Int 64 (2003) 314-320
195. McLaughlin P.J., Aikawa A., Davies H.M., Ward R.G., Bakran A., Sells R.A., et al. Evaluation of sequential plasma and urinary tumor necrosis factor a levels in renal allograft recipients. Transplantation 51 (1991) 1225-1229
196. Oliveira J.G., Xavier P., Sampaio S.M., Mendes A.A., and Pestana M. sTNFRI and sTNFRII synthesis by fine-needle aspiration biopsy sample cultures is significantly associated with acute rejection in kidney transplantation. Transplantation 71 (2001) 1835-1839
197. Suzuki J., Cole S.E., Batirel S., Kosuge H., Shimizu K., Isobe M., et al. Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 3 (2003) 968-976
198. Eason J.D., Wee S., Kawai T., Hong H.Z., Powelson J.A., Widmer M.B., et al. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 59 (1995) 300-305
199. Pascher A., and Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFα inhibitors?. BioDrugs 19 (2005) 211-231
200. Sankaran D., Asderakis A., Ashraf S., Roberts I.S., Short C.D., Dyer P.A., et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 56 (1999) 281-288
201. Pelletier R., Pravica V., Perrey C., Xia D., Ferguson R.M., Hutchinson I., et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 70 (2000) 674-680
202. Poli F., Boschiero L., Giannoni F., Tonini M., Scalamogna M., Ancona G., et al. Tumour necrosis factor-α gene polymorphism: implications in kidney transplantation. Cytokine 12 (2000) 1778-1783
203. Poli F., Boschiero L., Giannoni F., Tonini M., Ancona G., Scalamogna M., et al. TNF-α, IFN-γ, IL-6, IL-10, and TGF-β1 gene polymorphisms in renal allografts. Transplant Proc 33 (2001) 348-349
204. Hahn A.B., Kasten-Jolly J.C., Constantino D.M., Graffunder E., Singh T.P., Shen G.K., et al. TNF-α, IL-6, IFN-γ, and IL-10 gene expression polymorphisms and the IL-4 receptor α-chain variant Q576R: effects on renal allograft outcome. Transplantation 72 (2001) 660-665
205. Alakulppi N.S., Kyllonen L.E., Jantti V.T., Matinlauri I.H., Partanen J., Salmela K.T., et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 78 (2004) 1422-1428
206. Park J.Y., Park M.H., Park H., Ha J., Kim S.J., and Ahn C. TNF-α and TGF-β1 gene polymorphisms and renal allograft rejection in Koreans. Tissue Antigens 64 (2004) 660-666
207. Tinckam K., Rush D., Hutchinson I., Dembinski I., Pravica V., Jeffery J., et al. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. Transplantation 79 (2005) 836-841
208. Pawlik A., Domanski L., Rozanski J., Florczak M., Dabrowska-Zamojcin E., Dutkiewicz G., et al. IL-2 and TNF-α promoter polymorphisms in patients with acute kidney graft rejection. Transplant Proc 37 (2005) 2041-2043
209. Dmitrienko S., Hoar D.I., Balshaw R., and Keown P.A. Immune response gene polymorphisms in renal transplant recipients. Transplantation 80 (2005) 1773-1782
210. Wramner L.G., Norrby J., Hahn-Zoric M., Ahlmen J., Borjesson P.A., Carlstrom J., et al. Impaired kidney graft survival is associated with the TNF-α genotype. Transplantation 78 (2004) 117-121
211. Pawlik A., Domanski L., Rozanski J., Florczak M., Wrzesniewska J., Dutkiewicz G., et al. The cytokine gene polymorphisms in patients with chronic kidney graft rejection. Transpl Immunol 14 (2005) 49-52
212. Stone J.H. Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis. Kidney Blood Press Res 26 (2003) 240-248